NASDAQ •
Healthcare •
Drug Manufacturers - Specialty & Generic •
Quote as of 07/24/2026
Company Profile
IndustryDrug Manufacturers - Specialty & Generic
SectorHealthcare
ExchangeNASDAQ
Market Capitalization11.51 mln
Float0.77 mln
Earnings Date05/12/2026
Piotroski F-Score
4
/ 9
Borderline
Beneish M-Score
-3.4
Reliable
Relative Strength
91
/ 100
Top performer
Debt / Equity
0.06
Debt-free
ROE
-87.67
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
InMed Pharmaceuticals is a Canadian drug development company focused on creating medicines derived from rare cannabinoids, operating both a research division and a commercial manufacturing business. Its most advanced drug candidate is a topical cream called INM-755, designed to treat a rare and painful skin condition called epidermolysis bullosa, which has already completed a Phase 2 clinical trial. The company is also working on treatments for eye disease, Alzheimer's, and other neurological conditions, while its commercial arm supplies rare cannabinoid ingredients to the broader health and wellness market.